News | July 30, 2025
Ajanta Pharma reports Q1 FY26 consolidated PAT at Rs. 255.34 Cr
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
_256_384.jpg)
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
Revenue increased 11.4 per cent to Rs. 8,545 crore
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Subscribe To Our Newsletter & Stay Updated
